Streetwise Reports (02/02/2026)
Blue Lagoon Resources Inc. (BLLG:CSE; BLAGF:OTCQB; 7BL:FSE) said its milling partner, Nicola Mining Inc. (NIM:TSX.V; HUSIF:OTCQB; HLIA:FSE), is shifting its capacity exclusively to processing material from the Dome Mountain project. The move followed initial deliveries, a nearly CA$1 million payment, and continued underground production ramp-up. Streetwise Reports (02/02/2026)
Vanguard Mining Corp. (UUU:CSE; UUUFF:OTC; SL51:FWB) reported assay results from its 2025 Phase 1 diamond drilling program at the Redonda Copper-Molybdenum Project in British Columbia. The results from holes 25-01 and 25-02 showed lateral and vertical extension of mineralization, with the system remaining open at depth. Streetwise Reports (02/02/2026)
Emerita Resources Corp. (EMO:TSX.V; EMOTF:OTCQX; LLJA:FSE)began trading on the OTCQX Market in the United States as of January 30, 2026. The company said the move enhances visibility as it advances its Iberian Belt West project through permitting and prefeasibility. Streetwise Reports (02/02/2026)
NexGold Mining Corp. (NEXG:TSX.V; NXGCF:OTCQX; TRC1:FSE) has launched a 25,000-meter diamond drill program at its Goliath Gold Complex in Ontario, targeting high-grade zones within the Goldlund Deposit. The initiative comes amid surging gold prices and increasing global demand, with the company aiming to optimize resources and unlock additional value across the project. Streetwise Reports (02/02/2026)
Copper Giant Resources Corp. (CGNT:TSXV; LBCMF:OTCQB) reported new drill results from its Mocoa copper molybdenum project in Colombia, including grades above the 2026 resource model at the southern edge of the deposit. The results concluded the company's 2025 drilling program and confirmed mineralization continuity beyond the current resource footprint. Streetwise Reports (02/02/2026)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year.